Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells 6,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $16.45, for a total transaction of $98,700.00. Following the sale, the general counsel now directly owns 105,386 shares of the company's stock, valued at approximately $1,733,599.70. This trade represents a 5.39 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Centessa Pharmaceuticals Stock Down 3.3 %

Shares of NASDAQ CNTA traded down $0.54 during mid-day trading on Friday, reaching $15.75. 1,555,582 shares of the company's stock traded hands, compared to its average volume of 526,428. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The business has a 50-day simple moving average of $16.47 and a 200 day simple moving average of $16.40. The stock has a market cap of $2.08 billion, a P/E ratio of -10.29 and a beta of 1.54. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. purchased a new stake in shares of Centessa Pharmaceuticals in the fourth quarter worth approximately $31,000. GAMMA Investing LLC raised its position in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after buying an additional 865 shares during the last quarter. Barclays PLC lifted its stake in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Centessa Pharmaceuticals during the 4th quarter valued at $162,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Centessa Pharmaceuticals during the 4th quarter worth $171,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several brokerages recently issued reports on CNTA. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. Morgan Stanley reissued an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $26.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.